Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer.
Inflammation
pancreatic cancer
prognosis
systemic immune-inflammation index (SII)
Journal
Annals of translational medicine
ISSN: 2305-5839
Titre abrégé: Ann Transl Med
Pays: China
ID NLM: 101617978
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
entrez:
12
3
2021
pubmed:
13
3
2021
medline:
13
3
2021
Statut:
ppublish
Résumé
Pancreatic ductal adenocarcinoma (PDAC) detains a dismal prognosis and has a limited number of prognostic factors. Inflammation has been demonstrated to play a key role both in PDAC initiation and progression and several inflammation-based prognostic scores have been investigated in a wide range of malignancies. We compared the most analyzed inflammation-based prognostic scores in order to establish their potential impact on prediction of the outcome in advanced PDAC patients. A total of 234 advanced PDAC patients undergoing first-line chemotherapy in our institute were retrospectively analyzed. Baseline clinicopathological and pre-treatment laboratory data were collected. Survival was estimated using Kaplan-Meier method and survival differences were evaluated using the log-rank test. Level of statistical significance P was set at 0.05. Only those variables that proved to be associated with statistically significant differences in outcome were compared in multivariate analysis using multiple Cox regression, as to identify their independent role and their relative power against each other. In the whole cohort, median overall survival (OS) was 8.7 months (95% CI: 7.8-9.4 months), median progression-free survival (PFS) was 3.8 months (95% CI: 3.1-4.2 months). At univariate analysis high systemic immune-inflammation index (SII) was related to shorter OS [hazard ratio (HR) =2.04, 95% CI: 1.59-4.19, P=0.0001] and PFS (HR =1.52, 95% CI: 1.11-2.20, P=0.01). This was maintained at multivariate analysis both for OS (HR =2.11, 95% CI: 1.29-3.46, P=0.003) and PFS (HR =1.64, 95% CI: 1.14-2.37, P=0.008), whereas other inflammation-based scores lost their independent role. Elevated SII (≥1,200) was associated with low albumin levels (P=0.03) and with elevated lactate dehydrogenase (LDH) (P=0.01). Elevated SII represents an independent negative prognostic factor above all others for both OS and PFS in advanced PDAC patients treated with first-line chemotherapy, thus confirming a pivotal role of systemic inflammation on PDAC progression and on patient outcome.
Sections du résumé
BACKGROUND
BACKGROUND
Pancreatic ductal adenocarcinoma (PDAC) detains a dismal prognosis and has a limited number of prognostic factors. Inflammation has been demonstrated to play a key role both in PDAC initiation and progression and several inflammation-based prognostic scores have been investigated in a wide range of malignancies. We compared the most analyzed inflammation-based prognostic scores in order to establish their potential impact on prediction of the outcome in advanced PDAC patients.
METHODS
METHODS
A total of 234 advanced PDAC patients undergoing first-line chemotherapy in our institute were retrospectively analyzed. Baseline clinicopathological and pre-treatment laboratory data were collected. Survival was estimated using Kaplan-Meier method and survival differences were evaluated using the log-rank test. Level of statistical significance P was set at 0.05. Only those variables that proved to be associated with statistically significant differences in outcome were compared in multivariate analysis using multiple Cox regression, as to identify their independent role and their relative power against each other.
RESULTS
RESULTS
In the whole cohort, median overall survival (OS) was 8.7 months (95% CI: 7.8-9.4 months), median progression-free survival (PFS) was 3.8 months (95% CI: 3.1-4.2 months). At univariate analysis high systemic immune-inflammation index (SII) was related to shorter OS [hazard ratio (HR) =2.04, 95% CI: 1.59-4.19, P=0.0001] and PFS (HR =1.52, 95% CI: 1.11-2.20, P=0.01). This was maintained at multivariate analysis both for OS (HR =2.11, 95% CI: 1.29-3.46, P=0.003) and PFS (HR =1.64, 95% CI: 1.14-2.37, P=0.008), whereas other inflammation-based scores lost their independent role. Elevated SII (≥1,200) was associated with low albumin levels (P=0.03) and with elevated lactate dehydrogenase (LDH) (P=0.01).
CONCLUSIONS
CONCLUSIONS
Elevated SII represents an independent negative prognostic factor above all others for both OS and PFS in advanced PDAC patients treated with first-line chemotherapy, thus confirming a pivotal role of systemic inflammation on PDAC progression and on patient outcome.
Identifiants
pubmed: 33708878
doi: 10.21037/atm-20-3499
pii: atm-09-03-251
pmc: PMC7940927
doi:
Types de publication
Journal Article
Langues
eng
Pagination
251Informations de copyright
2021 Annals of Translational Medicine. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-20-3499). The authors have no conflicts of interest to declare
Références
World J Oncol. 2019 Feb;10(1):10-27
pubmed: 30834048
Korean J Fam Med. 2019 Sep;40(5):314-322
pubmed: 30959581
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Cells. 2019 Jul 13;8(7):
pubmed: 31337010
Cancer Discov. 2012 Dec;2(12):1091-9
pubmed: 23166151
Clin Lung Cancer. 2015 Nov;16(6):e165-71
pubmed: 25922292
Blood. 2014 Jul 10;124(2):184-7
pubmed: 24868077
Nat Rev Clin Oncol. 2019 Jan;16(1):11-26
pubmed: 30341417
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
J Immunol Res. 2015;2015:983698
pubmed: 26819959
Oncotarget. 2017 Mar 22;8(38):64499-64508
pubmed: 28969089
J Transl Med. 2019 Jan 18;17(1):30
pubmed: 30658662
Clin Transl Med. 2019 Jan 15;8(1):2
pubmed: 30645701
Cancer. 2009 Jun 15;115(12):2630-9
pubmed: 19353729
Int J Gynecol Cancer. 2017 Sep;27(7):1399-1407
pubmed: 28604454
Br J Cancer. 2012 Apr 10;106(8):1439-45
pubmed: 22433965
J Hematol Oncol. 2018 Oct 11;11(1):125
pubmed: 30305116
Clin Transl Radiat Oncol. 2018 Apr 13;10:47-52
pubmed: 29928705
J Exp Clin Cancer Res. 2019 Apr 15;38(1):162
pubmed: 30987642
Clin Cancer Res. 2015 Feb 1;21(3):602-10
pubmed: 25473001
Anticancer Res. 2018 Oct;38(10):5883-5888
pubmed: 30275214
Carcinogenesis. 2015 Oct;36(10):1085-93
pubmed: 26354776
Lung Cancer. 2017 Sep;111:176-181
pubmed: 28838390
Cancers (Basel). 2019 Apr 19;11(4):
pubmed: 31010242
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Cancer Res. 2009 Jul 1;69(13):5383-91
pubmed: 19549917
Int J Cancer. 2016 Mar 1;138(5):1058-66
pubmed: 25784597
Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):E3053-61
pubmed: 25024172
Onco Targets Ther. 2018 Apr 05;11:1899-1908
pubmed: 29670365
Ann Oncol. 2015 Sep;26 Suppl 5:v56-68
pubmed: 26314780
Pancreatology. 2019 Jul;19(5):722-728
pubmed: 31153778
Surg Oncol. 2002 May;10(4):153-69
pubmed: 12020670
N Engl J Med. 2019 Jul 25;381(4):317-327
pubmed: 31157963
Saudi J Gastroenterol. 2019 Jan-Feb;25(1):3-13
pubmed: 30588953
Eur J Surg Oncol. 2000 Aug;26(5):474-9
pubmed: 11016469
Ann Transl Med. 2015 Dec;3(21):328
pubmed: 26734638
Sci Rep. 2017 Mar 27;7:45194
pubmed: 28345594
J Gastrointest Surg. 2020 Mar;24(3):610-618
pubmed: 30923999
Cancer. 2016 Jul 15;122(14):2158-67
pubmed: 27152949
Blood. 2018 Apr 19;131(16):1777-1789
pubmed: 29519806
BMC Cancer. 2013 Mar 27;13:158
pubmed: 23530866
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Int Immunopharmacol. 2018 Dec;65:503-510
pubmed: 30408627
Clin Chim Acta. 2018 Apr;479:181-189
pubmed: 29407690
Cancer Cell. 2018 Jun 11;33(6):965-983
pubmed: 29657130
World J Gastrointest Oncol. 2014 Feb 15;6(2):34-40
pubmed: 24567794
Cell Rep. 2018 Apr 17;23(3):808-822
pubmed: 29669286
Gut. 2013 Feb;62(2):310-6
pubmed: 21997559
Clin Transl Oncol. 2020 Jan;22(1):81-90
pubmed: 31004253